| European Medicines Agency - Eligible Group Status - COMP [Committee for Orphan Medicinal Products] - SAWP [Scientific Advice Working Party]. | 호흡기
> 폐 섬유증 | 규제 파트너십
> 규제 기관과의 협력 | Not specified | International | Rarely | 119039359117 |
| When new drugs are approved by the EU medicines agency, we work to represent patient interest with the health service and government agency responsible for approving the drug in Ireland and regulating pricing of new drugs. | 호흡기
> 간질성 폐질환(ILD) | 규제 파트너십
> 규제 기관과의 협력 | 5,000 | National | Sometimes | 119044171823 |
| Submission on Lutathera for reimbursement decision. | 암
> 암: 신경내분비 (NET) | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 1,000 | National | Rarely | 119039308095 |
| We share the patient experience of living with a condition as part of the reimbursement process. | 신경근
> 신경근육 질환: 대부분의 유형 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 1,000 | National | Sometimes | 119047368493 |
| We submitted our support to the NCPE [National Centre for Pharmacoeconomics] for their appraisal of Lutathera [used to treat adults with certain unresectable or metastatic gastroenteropancreatic neuroendocrine tumors]. | 암
> 암: 신경내분비 (NET) | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 100 | National | Rarely | 119051190597 |
| Drugs for ataxia are very rare, so we only make submissions as they become available. | 신경퇴행성
> 운동실조 | 규제 파트너십
> 마케팅 허가 제출에 기여 | 1,000 | National | Rarely | 119020208311 |
| European Medicines Agency - Eligible Group Status - COMP [Committee for Orphan Medicinal Products] - SAWP [Scientific Advice Working Party]. | 호흡기
> 폐 섬유증 | 규제 파트너십
> 정책 입안자/규제 기관과의 회의 참석/진행 | Not specified | International | Rarely | 119039359117 |
| Meetings with Government Representatives and Department of Health regarding the availability of certain DMTs [Disease-Modifying Therapies primarily used for multiple sclerosis and various autoimmune conditions (like rheumatoid arthritis)]. | 신경학적
> 다발성 경화증 | 규제 파트너십
> 정책 입안자/규제 기관과의 회의 참석/진행 | 10,000 | National | Regularly | 119074666617 |
| National organization is affiliated with European groups which attempt to have influence. | 일반 건강
> 건강 리터러시 | 규제 파트너십
> 다른 의료 지지자들과 함께 | 100 | National | Rarely | 119052876993 |
| Advocacy/public affairs messaging about improving reimbursement decision-making for drugs in Ireland. | 암
> 암: 대부분의 유형 | 정책 및 법률에 영향 미치기
> 의료 정책 및 법률에 영향력 행사 | 10,000 | National | Rarely | 119063937918 |
| We have advocated for our members to our government representatives at yearly events where we have been invited to government buildings to present to an invited group. | 환자 권익 옹호
> 건강 활동가 | 정책 및 법률에 영향 미치기
> 공청회 및 협의에 참여하기 | 5,000 | National | Rarely | 119047297038 |
| We have advocated for our members to our government representatives at yearly events where we have been invited to government buildings to present to an invited group. | 환자 권익 옹호
> 건강 활동가 | 정책 및 법률에 영향 미치기
> 의회 의원 및 정치 지도자 동원 | 5,000 | National | Rarely | 119047297038 |
| We advocate for the most efficient medicine to be available and reimbursed for heart failure patients. | 하트
> 심부전 | 정책 및 법률에 영향 미치기
> 의료 서비스의 장벽/이상 현상 해결 | 5,000 | National | Sometimes | 119051411038 |
| When new drugs are approved by the EU medicines agency, we work to represent patient interest with the health service and government agency responsible for approving the drug in Ireland and regulating pricing of new drugs. | 호흡기
> 간질성 폐질환(ILD) | 가격 책정 및 affordability 옹호
> 가격 검토 위원회 협상에 참여 | 5,000 | National | Sometimes | 119044171823 |
| Advocacy/public affairs messaging about improving reimbursement decision-making for drugs in Ireland. | 암
> 암: 대부분의 유형 | 가격 책정 및 affordability 옹호
> 제품의 급여 목록/국가 처방집 등재 옹호 | 10,000 | National | Rarely | 119063937918 |
| Equity of access: Public patients can wait a lot longer for access to meds approved by EMA [European Medicines Agency], versus private patients whose insurance companies reimburse. | 환자 권익 옹호
> 건강 활동가 | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | 1,000 | National | Sometimes | 119044976833 |
| We advocate for the most efficient medicine to be available and reimbursed for heart failure patients. | 하트
> 심부전 | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | 5,000 | National | Sometimes | 119051411038 |
| Meetings with Government Representatives and Department of Health regarding the availability of certain DMTs [Disease-Modifying Therapies primarily used for multiple sclerosis and various autoimmune conditions (like rheumatoid arthritis)]. | 신경학적
> 다발성 경화증 | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | 10,000 | National | Regularly | 119074666617 |
| Equity of access: Public patients can wait a lot longer for access to meds approved by EMA [European Medicines Agency], versus private patients whose insurance companies reimburse. | 환자 권익 옹호
> 건강 활동가 | 접근 경로 개선
> 접근성 및 관리의 불균형 해소 | 1,000 | National | Sometimes | 119044976833 |
| Drugs for ataxia are very rare, so we only make submissions as they become available. | 신경퇴행성
> 운동실조 | 접근 경로 개선
> 희귀/초희귀 치료제 접근성 개선 | 1,000 | National | Rarely | 119020208311 |
| During the course of projects based on issues experienced by the community. | 위장관
> IBD | 근거 기반 환자 의견
> 환자 이야기와 실제 경험 서사 활용 | 5,000 | National | Sometimes | 119020296590 |
| We share the patient experience of living with a condition as part of the reimbursement process. | 신경근
> 신경근육 질환: 대부분의 유형 | 근거 기반 환자 의견
> 환자 이야기와 실제 경험 서사 활용 | 1,000 | National | Sometimes | 119047368493 |
상호작용
활동 및 옹호
9 멘션
